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Background: Tuberculosis (TB) could be fatal if left untreated, however, adverse effects of
anti-TB medications (anti-TBs) themselves may limit treatment. We determined the inci-
dence and clinical characteristics of hepatotoxicity in hospitalized patients receiving
first-line anti-TB treatment.
Methods: A retrospective cohort study of patients agedP18 years seen at the medical wards
of the Jos University Teaching Hospital from January 2013 to June 2013 was carried out. Data
were retrieved for 110 patients who were prescribed anti-TBs. Their demographic and clin-
ical characteristics were described, and the incidence of symptomatic hepatotoxicity deter-
mined. The incidence of hepatotoxicity by strict American Thoracic Society criteria
(symptomatic hepatotoxicity plus alanine transaminase in IU/L levels >3  upper limit of
normal) was also determined.
Results: Twenty patients developed symptomatic hepatotoxicity, giving an incidence of
18.2%. Furthermore, 18 (16.4%) patients had hepatotoxicity according to the American Tho-
racic Society criteria. Those with symptomatic hepatotoxicity unexpectedly had lower
baseline alanine transaminase interquartile range (IQR) (35 [16–63] vs. 67 [4–226]; p = .04)
and bilirubin (lmol/L): total IQR (15.3 [10.2–74.8] vs. 20.4 [20.4–20.4]; p = .01) and conjugated
IQR (7.6 [5.1–34.8] vs. 10.2 [10.2–10.2]; p = .004). However, there were no significant differ-
ences in age, sex, body mass index, and duration of anti-TB treatment, human immunod-
eficiency virus infection status, antiretroviral therapy status, alcohol consumption, and the
presence of hepatitis B surface antigen or hepatitis C virus antibody.
Conclusion: Hepatotoxicity due to first-line anti-TBs, whether based on clinical features
alone or backed by liver chemistry, is common among hospitalized patients in our environ-
ment. Studies to determine the predictors of hepatotoxicity to guide clinical interventions
aimed at the prevention or timely identification of cases are needed.
 2015 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.
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Introduction
Tuberculosis (TB) is one of the most common infectious dis-
eases and there were an estimated 9 million incident cases
worldwide according to the global tuberculosis report of
2014 [1]. Since the scale-up of nationwide directly observed
treatment (DOTS) in 2002 in Nigeria, a total of 640,113 of all
forms of TB have been registered, with 90,447 notifications
(400/100,000 population) in 2008 alone [2]. The first line regi-
men which requires administration of a combination of
anti-TB medications (anti-TBs) for 6–9 months achieved a
treatment success rate of about 84%, a death rate of 5%, and
a defaulter rate of 8% in Nigeria [2]. The DOTS program, which
has established or strengthened linkages with tertiary hospi-
tals in recent years, is the major provider of TB treatment
using the standard short course chemotherapy [2].
Adverse drug reactions to anti-TBs could lead to treatment
interruptions with resultant poor outcomes, including the
risk of drug resistance [3]. Hepatotoxicity is one of the most
important adverse drug reactions associated with anti-TBs
[4], and depending on the definition of hepatotoxicity, the
incidence range is from 2% to 28% [5]. Although it may be
challenging to predict when hepatotoxicity will occur, it is
known that certain patient characteristics put them at higher
risk. These include hepatic abnormalities, like chronic hepati-
tis B virus and hepatitis C virus (HCV), disseminated TB, Asian
ethnicity, female sex, significant alcohol use, concurrent
administration of other hepatotoxic medications, being
elderly, and being malnourished [6–9]. Although human
immunodeficiency virus (HIV)/AIDS is significantly associated
with development of hepatotoxicity [10], the reason for this
association is obscure. However, this may be as a result of
excessive immune activation leading to less efficient han-
dling of oxidative stress and detoxification of drug metabo-
lites [11].
The advantage of regular monitoring of liver function test
(LFT) in patients receiving anti-TBs, especially in countries
where health budgets are meagre, has not been clearly estab-
lished. However, the prevention or early detection of hepato-
toxicity is important as morbidity and mortality can be
substantial among those with symptomatic hepatotoxicity.
Some guidelines only emphasize clinical monitoring while
others additionally recommend routine biochemical monitor-
ing at varying frequencies among the high risk groups [12,13].
Although there are attempts to improve the quality of patient
care under DOTS, data on anti-TB hepatotoxicity in Nigeria,
whether clinical or biochemical, are scarce. We describe the
incidence and the clinical and laboratory characteristics of
hospitalized patients receiving anti-TBs who developed hepa-
totoxicity at the Jos University Teaching Hospital (JUTH), Jos,
Nigeria.
Materials and methods
This was a retrospective cohort study of new TB cases aged
P18 years seen at the infectious diseases wards of JUTH from
January 2013 to June 2013 who were receiving first line anti-
TBs. Data were retrieved from the case notes of all of the110 patients seen in that period who met the inclusion crite-
done, however, it is only repeated in those who developed
hepatotoxicity or if there are other indications. The data col-
lected included: socio-demographic data (age, sex, and alco-
hol consumption), features of symptomatic hepatotoxicity
(including fatigue, loss of appetite, nausea, vomiting, right
hypochondrial pain/tenderness, fever, and jaundice), pul-
monary or extrapulmonary TB, HIV status, combination
antiretroviral therapy (cART) status, and body mass index
(BMI; kg/m2). Laboratory data included alanine transaminase
(ALT; IU/L), aspartate transaminase (IU/L), total and conju-
gated bilirubin (lmol/L), total serum protein and albumin
(g/L), hepatitis B surface antigen (HBsAg), and HCV antibody
(anti-HCV).
Diagnosis of TB was based on Ziehl–Neelsen sputum
smear microscopy, GeneXpert assay, or any combination
of clinical and radiological/pathological evidence. Hepato-
toxicity was defined as: (1) any combination of newly
developing or worsening features of symptomatic hepatitis
with a temporal relationship to anti-TB initiation without
an apparent alternative explanation; (2) a stricter increase
in serum ALT >3 times upper limit of normal (ULN)
together with features of symptomatic hepatitis according
to the American Thoracic Society (ATS) [13]. This is a part
of the ATS definition which also considers ALT >5 times
ULN in the absence of symptoms as hepatotoxicity. Our
laboratory normal reference for both ALT and aspartate
transaminase was <40 IU/L, and <17 lmol/L for total biliru-
bin. All admitted patients are routinely reviewed and the
diagnosis of hepatotoxicity was made by at least a spe-
cialty registrar.
We also excluded those who were not prescribed a stan-
dard anti-TB regimen or who were already on anti-TBs
before hospital admission. Standard anti-TB regimen is:
isoniazid, rifampicin, ethambutol, and pyrazinamide with
dosages decided according to the weight of the patient
[2]. Ethical approval was obtained from the JUTH Ethics
Committee.
Statistical analyses
Analyses were carried out using Stata software version 10.0
(Stata Corporation, College Station, TX, USA). The main out-
come variable was hepatotoxicity (symptomatic hepatitis
± ALT >3  ULN).
Baseline characteristics of the 110 patients were
described and the characteristics of patients with symp-
tomatic hepatitis were compared with those without. Con-
tinuous variables were presented as mean (standard
deviation [SD]) or as median (interquartile range [IQR])
while the categorical variables were presented as propor-
tions. Chi-square test or Fisher’s exact test was used to
determine the association between each categorical variable
and the outcome. Comparisons between two means or
between two medians were done using unpaired t test or
Mann–Whitney test. A p value <.05 was considered signifi-
cant for all tests.
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The baseline characteristics of all 110 patients are shown in
Table 1. There were 20 (18.2%) patients who developed symp-
tomatic hepatotoxicity, in which 10 (50%) manifested with
jaundice as part of the features of hepatotoxicity. Further-
more, 18 (16.4%) of the 20 patients met the stricter criteria
for hepatotoxicity. Therefore, the cumulative incidence of
hepatotoxicity based on clinical features alone was 18.2%,
whereas it was 16.4% according to the ATS criteria.
The characteristics of the 20 (18.2%) patients who devel-
oped symptomatic hepatotoxicity are compared with those
who did not in Table 2. The median age of patients with hep-
atotoxicity was slightly lower than that of those without
hepatotoxicity, although this difference was not significant,
35 (IQR 27–43) years vs. 37 (IQR 30–45) years; p = .34.
Although the proportion of females (10, 50%) was higher
among those with hepatotoxicity versus those withoutTable 1 – Baseline characteristics of 110 patients before start of
Characteristics
Age (years), median (IQR)
Sex
Male
Female
BMI (kg/m2), mean (SD)
Pulmonary TB
Present
Absent
Extra-pulmonary TB
Present
Absent
HIV status
Positive
Negative
cART
Yes
No
Alcohol consumption
Yes
No
HBsAg status
Positive
Negative
HCV antibody status
Positive
Negative
Liver function tests
ALT (IU/L), median (IQR)
AST (IU/L), median (IQR)
Total bilirubin (lmol/L), median (IQR)
Conjugated bilirubin (lmol/L), median (IQR)
Total protein (g/L), median (IQR)
Albumin (g/L), median (IQR)
Note: ALT = alanine transaminase; AST = aspartate transaminase; BM
HBsAG = hepatitis B surface antigen; HCV = hepatitis C virus; HIV = hum
deviation; TB = tuberculosis.(40, 44%), the difference was not significant; p = .65. Similarly,
the higher mean BMI of those with hepatotoxicity
(18.8 kg/m2, SD 3.4) was not significantly different from
those without hepatotoxicity (18.4 kg/m2, SD 3.8), p = .70.
The median duration of anti-TB treatment was the same
for those with hepatotoxicity compared with those without,
14.0 days (IQR 9–36) vs. 14 days (IQR 9–39), p = .60. Similarly,
there was no significant difference between those with/with-
out hepatotoxicity in HIV positive status (65% vs. 70.8%;
p = .61), those on cART (55% vs. 52.8%; p = .86), alcohol con-
sumption (35% vs. 32.6%; p = .84), HBsAg positivity (7.2% vs.
11.4%; p = .35), and HCV antibody positivity (0% vs. 2.9%;
p = > .99). Counterintuitively, those who did not have hepato-
toxicity in the course of treatment had significantly higher
baseline median ALT IQR (67 [4–226] vs. 35 [16–63]; p = .04)
and bilirubin: median total IQR (20.4 [20.4–20.4] vs. 15.3
[10.2–74.8]; p = 0.01) and median conjugated IQR (10.2
[10.2–10.2] vs. 7.6 [5.1–34.8]; p = .004).antituberculosis treatment.
N (%) Mean (SD)/median (IQR)
110 (100) 37 (30–45)
60 (54.6)
50 (45.4)
105 (95.5) 18.5 (3.7)
89 (81.0)
21 (19.0)
67 (61.0)
43 (39.0)
76 (69.7)
33 (30.3)
58 (53.2)
51 (46.8)
36 (33.0)
73 (67.0)
9 (10.7)
75 (90.4)
2 (2.4)
81 (97.6)
91 (82.7) 33 (18–64)
88 (80) 66.5 (35.0–109.5)
66 (60) 10.2 (10.2–10.2)
66 (60) 5.1 (5.1–5.1)
72 (65.5) 72.5 (63.0–78.0)
70 (63.6) 31 (25–36)
I = body mass index; cART = combination antiretroviral therapy;
an immunodeficiency virus; IQR = interquartile range; SD = standard
Table 2 – Characteristics of the 20 patients with or without antituberculosis hepatotoxicity.
Characteristics Hepatotoxicity
Yes No pb
N (%)a N (%)a
Age (years), median (IQR) 35 (25–77) 37 (19–78) .34
Sex .65
Male 10 (50.0) 50 (55.6)
Female 10 (50.0) 40 (44.4)
BMI (kg/m2), mean 18.8 (3.4) 18.4 (3.8) .70
Pulmonary TB .99
Present 16 (80) 73 (81.1)
Absent 4 (20.0) 17 (18.9)
Extrapulmonary TB .23
Present 10 (50.0) 57 (63.3)
Absent 10 (50.0) 33 (36.7)
Duration of anti-TB treatment (d), median (IQR) 14 (9–36)c 14 (9–39)d .60
HIV status .61
Positive 13 (65.0) 63 (70.8)
Negative 7 (35.0) 26 (29.2)
cART .86
Yes 11 (55.0) 47 (52.8)
No 9 (45.0) 42 (47.2)
Alcohol consumption .84
Yes 7 (35.0) 29 (32.6)
No 13 (65.0) 60 (67.4)
HBsAg status .35
Positive 1 (7.2) 8 (11.4)
Negative 13 (92.8) 62 (88.6)
HCV antibody status .99
Positive 0 (00.0) 2 (2.9)
Negative 13 (100) 68 (97.1)
Baseline liver function tests
ALT (IU/L), median (IQR) 35 (16.0–63.0) 67(4–226) .04
AST (IU/L), median (IQR) 66 (28–117) 81(6–293) .09
Total bilirubin (lmol/L), median (IQR) 15.3 (10.2–74.8) 20.4 (20.4–20.4) .01
Conjugated bilirubin (lmol/L), median (IQR) 7.6 (5.1–34.8) 10.2 (10.2–10.2) .004
Total protein (g/L), median (IQR) 66.5 (58.5–74.5) 56 (52–60) .42
Albumin (g/L), median (IQR) 30.5 (24–33.5) 16 (16–16) .19
Note: ALT = alanine transaminase; AST = aspartate transaminase; BMI = body mass index; cART = combination antiretroviral therapy;
HBsAG = hepatitis B surface antigen; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IQR = interquartile range;
TB = tuberculosis.
a This refers to the number (%) for categorical variables or the mean (standard deviation) or median (interquartile range) for continuous
variables.
b p value for chi-square test or Fisher’s exact test for the difference between categorical variables; or t-test or Mann–Whitney for the difference
between two means.
c Days on anti-TB until hepatotoxicity developed.
d Days on anti-TB until the last day of in-patient stay.
24 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 2 1 –2 6Discussion
We found an incidence of symptomatic hepatotoxicity of 18%
and a 16% incidence according to the ATS [13]. Makhlouf et al.
[14] similarly reported an incidence of 15%, but among out-
patients in Egypt. However, some investigators in Africa and
Asia found comparatively lower incidence of between 4%
and 11.5% [15–18]. By contrast, Yimer et al. [19] found a higher
prevalence of 30%, probably because the majority of patientsin their study were likely to have experienced the combined
hepatotoxic effects of anti-TBs and cART, compared with only
about 50% of patients receiving cART in the current study.
Variations in the reported rates of hepatotoxicity are also
likely as a result of differences in study design, patient char-
acteristics, diagnostic criteria for hepatotoxicity, and concur-
rent use of hepato-protective therapy with anti-TBs.
Although the mean BMI of patients with hepatotoxicity of
18.8 kg/m2 was not significantly different from 18.4 kg/m2 in
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nized risk factor for hepatotoxicity [8]. Problems with drug
absorption in wasted patients with advanced HIV/AIDS and
the imprecise, but practical, anti-TB dosing based on weight
bands might have confounded our findings. The median time
to the development of hepatotoxicity was 14 days (IQR 9–
36 days). This finding differs from those of other studies,
although with some overlap, which reported a median of
28 days and a range between 14 and 60 days [16,17]. The
observed difference could have arisen because we followed
our patients only while in hospital, a generally shorter period
of follow up compared with the 14–60 days it took for most
cases of hepatotoxicity to occur [16,17].
Some studies found older age as a risk factor for hepato-
toxicity [8,20,21]. However, our study, like some others
[7,20,21], did not find an association. The probable reason is
that our cohort is predominantly young where the median
age is <40 years. We did not find sex and BMI to be associated
with hepatotoxicity. Similar findings were previously reported
[13,14,22]. Nonetheless, females were thought to be at an
increased risk due to their lower BMI and slow acetylator sta-
tus [23,24].
Coinfection with hepatitis B virus, HCV, or HIV was not
found to be associated with hepatotoxicity in the current
study. Several other studies had clearly indicated that they
were risk factors for anti-TB hepatotoxicity [13,22,23]. How-
ever, there was only one patient with HBsAg and none with
anti-HCV antibody among those with hepatotoxicity in the
current study. Our study also did not find concomitant
antiretroviral therapy or alcohol consumption to be associ-
ated with hepatotoxicity. Hussain et al. [24] also did not find
alcohol as a significant risk factor. This is at variance with
studies that found them to be important risk factors for hep-
atotoxicity [23,25–27]. Surprisingly also, ALT and bilirubin
were significantly higher in those without hepatotoxicity.
Although abnormal baseline LFT is predictive of anti-TB hep-
atotoxicity [28], differences in abilities of individuals to
activate adaptive liver-protective mechanisms aimed at ame-
liorating effects of exposure to hepatotoxic agents [29] may
partly explain our finding. In addition, data on concurrent
use of other hepatotoxic medications or pre-existing liver dis-
ease were not assessed in the present cohort.
The present study has important limitations. Our findings
may not be widely generalizable as the data emanated from a
relatively few patients who were hospitalized in a single ter-
tiary hospital. The estimation of incidence was based on
symptomatic hepatotoxicity. Because LFT is not routinely
repeated following initiation of anti-TBs, patients with
asymptomatic hepatotoxicity [13] might have been missed.
It was therefore also not possible to determine if this group
of patients were at increased risk of progressing to the more
clinically relevant overt hepatotoxicity.
Conclusions
The incidence of symptomatic hepatotoxicity among our hos-
pitalized patients is high and ALT levels weremostly in excess
of 3 times ULN among cases. While doubts about the utility of
LFT in preventing or detecting hepatotoxicity may exist, closeclinical and laboratory monitoring are important in hospital-
ized patients. Appropriately designed studies to determine
the rates of both symptomatic and asymptomatic anti-TB
induced hepatotoxicity and their predictors are needed in
our environment.Conflicts of interest
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